Abstract: The present invention provides a triple vital bacteria composition, including: powder of Bifidobacterium longum, powder of Lactobacillus acidophilus, and powder of Streptococcus faecalis. The present invention further provides a method for preparing the above triple vital bacteria composition, as well as the protection agents, the fermenting culture medium and the seed culture medium used therein.

Abstract: The present technology relates to the use of at least one strain of probiotic bacteria selected from Lactobacillus for the manufacture of a medicament for the treatment and/or prevention of an autoimmune disease.

Abstract: This disclosure relates to enhancing growth and/or activity of lactobacilli using a prebiotic formulation which includes iso-malto oligosaccharides and ?-galactosidase; and to enhancing growth and/or activity of bifidobacteria using a prebiotic formulation which includes iso-malto oligosaccharides and ?-glucanase. Other combinations of fibers and enzymes are described below which also stimulate growth and activity of lactobacilli or bifidobacteria. These combinations of enzymes and prebiotics can be taken separately or added to foods, including desserts.

Abstract: The invention relates to the area of health-beneficial preparations and production methods thereof, in particular to the use of thermally pre-treated Lactobacillus preparations having specific bonding capacity for Streptococcus mutans for caries prophylaxis. The invention further relates to the Lactobacillus preparations and thermal pasteurization.

Abstract: According to the invention there is provided a strain of lactic acid bacteria of the genus Lactobacilli obtainable by isolation from resected and washed canine gastrointestinal tract having a probiotic activity in animals. Methods of use and compositions comprising the Lactobacilli of the present invention are also provided.

Abstract: Methods and apparatus for providing a leak-proof seal for two-piece capsules containing oil-based liquids or other compositions by a two-stage process. The capsule cap and capsule body are combined by a nitrogen purge instant bonding (NPIB) system. An overlay medium is applied to selected portions of the capsule, including near the seam formed by the interconnection of the capsule cap and capsule body to provide a substantially leak-proof seal. The overlay medium is made from materials that make up the capsule cap and capsule body, including gelatin, starch, cellulose or polysaccharides, among others, which are dispersed in a hydro-alcoholic, aqueous or organic solution. The overlay medium includes additives to impart desired qualities to the capsule and include taste-enhancers, taste-maskers, odor-enhancers and odor-maskers. The additives may include color additives, aroma additives and taste additives.

Abstract: This disclosure relates to enhancing growth and/or activity of lactobacilli using a prebiotic formulation which includes iso-malto oligosaccharides and ?-galactosidase; and to enhancing growth and/or activity of bifidobacteria using a prebiotic formulation which includes iso-malto oligosaccharides and ?-glucanase. Other combinations of fibers and enzymes are described below which also stimulate growth and activity of lactobacilli or bifidobacteria. These combinations of enzymes and prebiotics can be taken separately or added to foods, including desserts.

Abstract: Probiotic microorganisms are micro encapsulated by dispersing the probiotic microorganism in an aqueous suspension of a film forming protein and a carbohydrate; in an oil in water emulsion of a film forming protein and a carbohydrate and a fat; or in an oil which is subsequently dispersed in a film forming protein and a carbohydrate. The emulsion or suspension may be dried to form a powder. The probiotic may be dispersed in oil and then emulsified with the aqueous suspension and then dried to produce an encapsulated oil be dried to produce a powder. Oil suspended probiotics may be preferred where the probiotic is water sensitive. The preferred protein is casein or whey protein and the carbohydrate may be a resistant starch or a saccharide with a reducing sugar group. Where the probiotic is oxygen sensitive the protein carbohydrate is heated to create Maillard reaction products in the encapsulating film.

Abstract: Disclosed are formulations for enhancing the in vivo colonization of probiotic microorganisms that include digestive enzymes and probiotic microorganisms, and polysorbate surfactants. The enzymes include lactogenic enzyme formulations that promote growth of Lactobacillus probiotics, bifidogenic enzyme formulations that promote growth of Bifidobacterium probiotics and combination formulations that benefit both types of probiotics. It has been discovered that certain polysorbate surfactants, including polysorbate-60 and polysorbate-80, further promote probiotic microorganism growth, when used with the enzyme formulations. The formulations are preferably compounded as dry powders, to avoid water reaction with the enzymes in blended formulations. Such formulations can be contained in capsules, tablets, packets or bottles and administered orally, either sequentially or in one combined formulation.

Abstract: New strains of Lactobacillus that have been selected for their capability of improved reduction the number of Streptococcus mutans in the mouth of mammals through inhibiting activity in combination with better binding to the oral mucins and dental plaque, thereby preventing, reducing or treating dental caries, and products derived from said strains, including agents for treatment or prophylaxis of caries for administration to humans.

Abstract: The invention relates to a novel strain of Lactobacillus delbrueckii having blood-cholesterol-lowering properties, and to the use thereof for the manufacture of blood-cholesterol-lowering fermented products, in particular of milk products.

Abstract: A subject of the invention is a composition containing strains Lactobacillus fermentum 57A, Lactobacillus plantarum 57B and Lactobacillus gasseri 57C of special characteristics such as a feature of strong diversified affinity for the digestive tract and vaginal epithelia enabling the colonization of the vagina and anus after the crossover through intestines as well as the feature of co-aggregation enabling for synergetic activity. The subject of the invention is also the application of the composition for restoration of the natural bacterial flora of the vagina and anus.

Abstract: Dairy compositions are provided having a high pH, of about 4.8 to about 6.2, comprising desirable probiotic cultures as well as an anti-microbial system for inhibiting undesirable pathogenic and/or spoilage microbial growth without significantly reducing the beneficial effect of the probiotic cultures.

Abstract: The use of a probiotic Lactobacillus rhamnosus and a probiotic Bifidobacterium longumin the manufacture of a medicament or therapeutic nutritional composition for administration to an infant during at least the first three months of life for the long-term prophylaxis of diarrhea in infants and young children.

Abstract: The present invention relates generally to the field of nutrition, more particularly to the use of probiotics in nutrition. In particular the present invention relates to the use of a probiotic or of a mixture of probiotics in the manufacture of a nutritional composition or a medicament to act the colon in a pre- or post surgical environment.

Abstract: The invention relates to an infant formula comprising a source of protein in an amount of not more than 2.0 g/100 kcal, a source of lipids, a source of carbohydrate and a probiotic wherein the probiotic is present in an amount equivalent to between 102 and 105 cfu/g of dry formula. The invention further extends to the use of such an infant formula to modulate the immune system of a neonatal infant to promote the development in the first few weeks of the life of the infant of a beneficial intestinal microbiota comparable with that found in breast fed babies as well as to promote the maturation of the immune system of a neonatal infant in the first few weeks of life.

Abstract: Dairy compositions are provided having a high pH, of about 4.8 to about 6.2, comprising desirable probiotic cultures as well as an anti-microbial system for inhibiting undesirable pathogenic and/or spoilage microbial growth without significantly reducing the beneficial effect of the probiotic cultures.

Abstract: New strains of Lactobacillus that have been selected for their capability of improved reduction the number of Streptococcus mutans in the mouth of mammals through inhibiting activity in combination with better binding to the oral mucins and dental plaque, thereby preventing, reducing or treating dental caries, and products derived from said strains, including agents for treatment or prophylaxis of caries for administration to humans.

Abstract: The present invention relates to the novel Sporolactobacillus vineae SL153 strain (Accession No: KCTC 11493BP) having probiotic activity, precisely Sporolactobacillus vineae SL153 having antimicrobial activity against Vibrio genus pathogenic microorganisms and other pathogens. The Sporolactobacillus vineae SL153 strain of the present invention has excellent intestinal adherence and growth inhibitory effect on pathogenic microorganisms including Vibrio genus microorganisms, so that it can be effectively used as a composition for the prevention and treatment of disease caused by pathogenic microorganisms.

Abstract: The invention relates to a composition for modulating the immune responses induced by Gram negative bacteria, potential pathogenic Gram positive bacteria and/or their derivatives, comprising lipoteichoic acid from lactic acid bacteria as an active ingredient. It also relates to the use of a lipoteichoic acid from lactic acid bacteria as an active ingredient and/or lactic acid bacteria producing it and/or its supernatant of culture, in the manufacture of a medicament, an oral or topical product for cosmetic, dermatological or ophtalmological applications, a food or petfood composition for modulating bacterial colonization, immune responses and decreasing the inflammatory processes associated with bacterially-mediated disease and infection in the gastrointestinal tract, bone, skin, eye, ear, lung and oral cavity. The invention also relates to lipoteichoic acid selected thereof.

Abstract: A nutritional formula which includes a lipid or fat; a protein source; about 5 to about 100 mg/100 kcal of a source of long chain polyunsaturated fatty acids which comprises docosahexanoic acid; about 0.1 to about 1 mg/100 kcal of a prebiotic composition, wherein the prebiotic composition comprises at least 20% of an oligosaccharide which comprises galacto-oligosaccharide; and about 0.015 to about 0.1 (pg/?g) ppm of TGF-?.

Abstract: Disclosed are methods of identifying peptides and compositions that bind to oocytes of animals in a species-specific manner. The methods utilize phage libraries and oocytes isolated from target species and non-target species.

Abstract: Sunflower lecithin or sunflower lecithin with oleic acid stimulate the growth and lactic acid producing activity of Lactobacillus and Bifidobacterium species of probiotic bacteria, and replace polysorbate 80 for those products. They can be used in naturally occurring form, or, where they are to be combined with probiotics in a carrier, they can preferably be adsorbed to carriers to yield a stable powdered form of these naturally oily compounds. They can be sold as combined prebiotic/probiotic formulations in the same carrier, or sold as separate dietary supplements, e.g., in capsule or tablet form, to be used with the probiotic formulation as desired.

Abstract: Sunflower lecithin or sunflower lecithin with oleic acid stimulate the growth and lactic acid producing activity of Lactobacillus and Bifidobacterium species of probiotic bacteria, and replace polysorbate 80 for those products. They can be used in naturally occurring form, or, where they are to be combined with probiotics in a carrier, they can preferably be adsorbed to carriers to yield a stable powdered form of these naturally oily compounds. They can be sold as combined prebiotic/probiotic formulations in the same carrier, or sold as separate dietary supplements, e.g., in capsule or tablet form, to be used with the probiotic formulation as desired.

Abstract: The invention relates to a probiotic health or fitness promoting human or animal foodstuff and/or drinking water additive, comprising a mixture of microorganisms, selected from the group Enterococcus faecium, DSM 16211, Lactobacillus reuteri, DSM 16350, Lactobacillus salivarius ssp. salivarius, DSM 16351, Pediococcus acidilactici, DSM 16210, Bifidobacterium animalis and DSM 16284. The invention further relates to a use of the human or animal foodstuff and/or drinking water additive, in particular for prevention of the harmful effect of a number of undesirable germs in the digestive system of animals and/or domestic birds.

Abstract: Disclosed are formulations for enhancing the in vivo colonization of probiotic microorganisms that include digestive enzymes and probiotic microorganisms, and polysorbate surfactants. The enzymes include lactogenic enzyme formulations that promote growth of Lactobacillus probiotics, bifidogenic enzyme formulations that promote growth of Bifidobacterium probiotics and combination formulations that benefit both types of probiotics. It has been discovered that certain polysorbate surfactants, including polysorbate-60 and polysorbate-80, further promote probiotic microorganism growth, when used with the enzyme formulations. The formulations are preferably compounded as dry powders, to avoid water reaction with the enzymes in blended formulations. Such formulations can be contained in capsules, tablets, packets or bottles and administered orally, either sequentially or in one combined formulation.

Abstract: Mutants of lactic acid bacteria including Lactococcus lactis which are defective in pyruvate formate-lyase production and/or in their lactate dehydrogenase (Ldh) production and methods of isolating such mutants or variants are provided. The mutants are useful in the production of food products or in manufacturing of compounds such as diacetyl, acetoin and acetaldehyde and as components of food starter cultures.

Abstract: The invention described relates to novel strains of lactic acid bacteria and their use in anti-allergy. The composition may be in the form of foodstuffs or in the form of pharmaceutical compositions.

Abstract: The invention relates to the use of at least one strain of lactic acid bacteria and/or bifidobacteria having hydrophobic surface properties, for the preparation of a composition intended for the prevention or the treatment of endotoxin mediated and/or associated disorders and human or pet food compositions prepared thereof.

Abstract: According to the invention there is provided a strain of lactic acid bacteria of the genus Lactobacilli obtainable by isolation from resected and washed canine gastrointestinal tract having a probiotic activity in animals. Methods of use and compositions comprising the Lactobacilli of the present invention are also provided.

Abstract: Disclosed herein are two Lactobacillus isolates having anti-inflammatory activities and beneficial probiotic properties, i.e., Lactobacillus sakei GMNL-76 and Lactobacillus reuteri GMNL-89, which were deposited in the Biosource Collection and Research Center (BCRC) of the Food Industry Research and Development Institute (FIRDI) under accession numbers BCRC 910355 and BCRC 910340 and in the China Center for Type Culture Collection (CCTCC) under accession numbers CCTCC M 207153 and CCTCC M 207154, respectively. The two Lactobacillus isolates and their sub-cultured offspring can be used in the preparation of a variety of food products, and in the manufacture of pharmaceutical compositions for treating and/or alleviating diseases associated with inflammation, such as rheumatoid arthritis.

Abstract: The present invention relates to a composition including a microbial component and a foaming component, wherein the composition can be used to prevent the proliferation, or otherwise competitively exclude the continued growth of, undesirable microbes. The present invention also includes a method of using this composition.

Abstract: One embodiment of the present invention is directed to the use of a novel competitive exclusion bacterial composition to prevent or reduce Salmonella or Campylobacter colonization in poultry.

Abstract: An additive for feeds is provided which is efficacious in preventing and ameliorating digestive disorders such as diarrhea occurring as the side effects of the administration of antibiotics and a feed containing same. More specifically, an additive for feeds which comprises (A) Lactobacillus equi cells and (B) cells of at least one bacterium selected from the group consisting of Lactobacillus salivarius, Lactobacillus crispatus and Lactbacillus johnsonii.

Abstract: The present invention relates to the use of lactic acid bacteria capable of adhering to the mucosa of the intestine and especially colonizing it for the prevention of peritonitis. In particular, the present invention relates to the use of such lactic acid bacteria for the prevention of peritonitis caused by cirrhosis of the liver. Specifically, the present invention relates to a method for preventing peritonitis in a patient in need of such prevention. This method includes administering to the patient a lactic acid bacterium that is capable of adhering to the intestine's mucosa and essentially colonizing it for the preparation of an ingestable carrier. The invention also relates to a peritonitis preventing composition of a lactic acid bacterium that is capable of adhering to the intestine's mucosa and essentially colonizing it for the preparation of an ingestable carrier. The carrier is preferably a food or pharmaceutical composition.

Abstract: A Lactobacillus paracasei-containing product used for inhibiting dental diseases caused by bacteria is provided, which comprises a plurality of Lactobacillus paracasei for inhibiting the growth of bacteria of dental diseases. Particularly, foods, oral hygiene products or oral treatment medicine containing the Lactobacillus paracasei when being administered or applied to a user can inhibit or reduce the number of pathogens of dental caries and periodontal diseases in oral cavity of the user, thereby achieving the efficacy of preventing dental diseases, such as dental caries and periodontal diseases.

Abstract: The invention relates to the use of at least one strain of lactic acid bacteria and/or bifidobacteria having hydrophobic surface properties, for the preparation of a composition intended for the prevention or the treatment of endotoxin mediated and/or associated disorders and human or pet food compositions prepared thereof.

Abstract: New strains of Lactobacillus that have been selected for their capability of improved reduction the number of Streptococcus mutans in the mouth of mammals through inhibiting activity in combination with better binding to the oral mucins and dental plaque, thereby preventing, reducing or treating dental caries, and products derived from said strains, including agents for treatment or prophylaxis of caries for administration to humans.

Abstract: The invention provides novel lactic acid bacteria having immunoregulating activities and usable in food and drinks, medicaments, and other applications. Specifically, the invention provides novel lactic acid bacteria separated from “Shibazuke,” one kind of traditional Kyoto pickles, and having immunoregulating activities. The lactic acid bacteria of the present invention belong to Lactobacillus pentosus.

Abstract: The present invention relates to a novel process for the selection of new probiotic strains which comprises the following steps: a) selecting for non-pathogenic strains which are capable of surviving in breast milk and/or amniotic fluid, and b) selecting for non-pathogenic strains which are able to be transferred to breast milk and/or amniotic fluid after oral intake in healthy individuals without colonizing other internal organs except mucousas. The invention also provides new Lactobacillus strains, which are: CECT5711 (Lactobacillus coryniformis), CECT5713 (Lactobacillus salivarius subsp. salivarius), CECT5714: (Lactobacillus gasseri, formerly L. acidophilus), CETC5715: (Lactobacillus gasseri), and CECT5716: (Lactobacillus fermentum); and refers to their use for the prophylaxis or treatment against digestive, infective, neuro-degenerative and immune related diseases such as allergies or inflammatory diseases.

Abstract: Mutants of lactic acid bacteria including Lactococcus lactis which are defective in pyruvate formate-lyase production and/or in their lactate dehydrogenase (Ldh) production and methods of isolating such mutants or variants are provided. The mutants are useful in the production of food products or in the manufacturing of compounds such as diacetyl, acetoin and acetaldehyde and as components of food starter cultures.

Abstract: The invention herein provides certain strains of lactic acid bacteria selected for their capability of promoting production of IL-10 and consequently proliferation of CD4+CD25+ TR cells, for prophylaxis and/or treatment of infant colic, a method of selecting such strains, and products containing such strains.

Abstract: The present invention provides an isolated microorganism strain, Lactobacillus fermentum GM-090, which is found to be effective in stimulating IFN-? secretion and/or treating allergy. The use of the Lactobacillus fermentum GM-090 in stimulating IFN-? secretion and/or treating allergy is also provided.

Abstract: Strains of lactic acid bacteria selected for their capability of reducing inflammation, such as intestinal bowel disease, a method of selecting such strains, and products containing such strains.

Abstract: The invention provides a composition comprising novel lactic acid bacteria having immunoregulating activities. Specifically, the invention provides food, drinks or medicaments containing novel lactic acid bacteria separated from “Shibazuke,” one kind of traditional Kyoto pickles, and having immunoregulating activities. The lactic acid bacteria belong to Lactobacillus pentosus and have a weak assimilating activity or no assimilating activity for glycerol.

Abstract: The present invention relates to the use of lactic acid bacteria capable of adhering to the mucosa of the intestine and especially colonizing it for the prevention of peritonitis. In particular, the present invention relates to the use of such lactic acid bacteria for the prevention of peritonitis caused by cirrhosis of the liver. Specifically, the present invention relates to a method for preventing peritonitis in a patient in need of such prevention. This method includes administering to the patient a lactic acid bacterium that is capable of adhering to the intestine's mucosa and essentially colonizing it for the preparation of an ingestable carrier. The invention also relates to a peritonitis preventing composition of a lactic acid bacterium that is capable of adhering to the intestine's mucosa and essentially colonizing it for the preparation of an ingestable carrier. The carrier is preferably a food or pharmaceutical composition.

Abstract: A strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. The strain is useful in the prophylaxis and/or treatment of undesirable inflammatroy activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer.

Abstract: The subject of the present invention is a bacterial composition having immunomodulation properties comprising at least one strain selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis PTA-4802. An other subject of the invention is an immunomodulation method comprising the step of using the at least one strain selected from the preceding group.

Abstract: Novel microorganisms of the family Lactobacillaceae, particularly microorganisms of the gnus Lactobacillus, that are useful in preventing or treating diarrhoea are provided. The microorganism can be utilized for the preparation of an ingestable support and to a composition containing same. The microorganism Lactobacillus paracasei CNCM I-2116 can be included.

Abstract: The present invention relates a novel Lactobacillus sp. strain and use thereof. More specifically, the present invention relates to a novel Lactobacillus sp. strain, Lactobacillus paracasei, isolated and identified from Kimchi fermentation liquid and uses thereof as probiotics, feeding additive, deodorizing agent and food additive. Lactobacillus paracasei of the present invention has good acid-resistance, bile acid-resistance and stability in the human body, has pathogenic bacteria inhibiting activity, increases numbers of beneficial bacteria by changing intestinal microflora and decreases diarrhea incidence, deodorizes offensive odor, and has effectes of softening and deodorizing in meat and fish.